<DOC>
	<DOCNO>NCT00093171</DOCNO>
	<brief_summary>The primary objective clinical research study assess safety efficacy rFIX minimum 6 month previously treat patient ( PTPs ) hemophilia B ( FIX : C ≤2 % ) standard-of-care treatment ( on-demand , prophylaxis , major minor surgical procedure ) .</brief_summary>
	<brief_title>Study Evaluating rFIX ; BeneFIX® Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Hemophilia B ( FIX : C le 2 % ) Previous treatment least 150 exposure day use FIX product 12 year age older The patient currently detectable factor IX inhibitor history inhibitor . ( A family history inhibitor exclude patient ) Known hypersensitivity protein pharmaceutical agent related test article , e.g . hamster proteins Patient genetic coagulation disorder hemophilia B</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>